TRGNF - Transgene reports positive early data from phase 1 trial of cancer vaccine

Transgene (OTCPK:TRGNF) says that early results from two phase 1 trials of TG4050, its neoantigen cancer vaccine, indicated clinical activity and anti-tumor cellular immune responses in six patients. The patients treated had ovarian or head and neck cancer. Primary endpoints in the trials were safety and feasibility. Secondary endpoints included biological activity. One of the four patients in the ovarian cancer trial treated after an elevation of CA-125 (cancer antigen 125) experienced a normalization of CA-125. Another with radiological lesions is stable and is continuing treatment nine months after starting. The two patients in the head and neck cancer trial have been treated for 10 and five months, respectively, and are stable.

For further details see:

Transgene reports positive early data from phase 1 trial of cancer vaccine